Lymphoid Interstitial Pneumonia: Clinical Trials

3 trials for Lymphoid Interstitial Pneumonia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 1 completed. 3 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 33Active not recruiting 2, Completed 1
Phase 21Active not recruiting 1

Follow Lymphoid Interstitial Pneumonia: new trials by email Literature Review of Lymphoid Interstitial Pneumonia trials Research Report on Lymphoid Interstitial Pneumonia

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
Atezolizumab, Bevacizumab, Biospecimen Collection - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma
Phase 2 / Phase 3Active not recruitingNational Cancer Institute (NCI)4302023-03-132026-11-12
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Bevacizumab, Carboplatin, Cisplatin - Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma
Phase 3Active not recruitingNational Cancer Institute (NCI)4032008-08-082026-11-13
Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer
pilocarpine hydrochloride, Placebo - Head and Neck Cancer, Oral Complications
Phase 3CompletedRadiation Therapy Oncology Group2491998-03-012015-11-17

Narrower conditions

Squamous Cell Carcinoma of Head and Neck (3)  ·  Carcinoma (1)  ·  Head and Neck Neoplasms (1)  ·  Hypopharyngeal Neoplasms (1)  ·  Laryngeal Neoplasms (1)  ·  Mouth Neoplasms (1)  ·  Nasopharyngeal Carcinoma (1)  ·  Oropharyngeal Neoplasms (1)  ·  Salivary Gland Neoplasms (1)  ·  Tongue Neoplasms (1)

Broader conditions

Carcinoma, Squamous Cell (3)  ·  Neoplasms (3)  ·  Neoplasms by Histologic Type (3)  ·  Neoplasms by Site (3)  ·  Neoplasms, Glandular and Epithelial (3)  ·  Carcinoma (2)  ·  Head and Neck Neoplasms (2)  ·  Mouth Diseases (2)  ·  Stomatognathic Diseases (2)  ·  Laryngeal Diseases (1)  ·  Mouth Neoplasms (1)  ·  Nasopharyngeal Diseases (1)  ·  Nasopharyngeal Neoplasms (1)  ·  Otorhinolaryngologic Diseases (1)  ·  Otorhinolaryngologic Neoplasms (1)

Interventions

1,2-diaminocyclohexaneplatinum II citrate (2)  ·  Bevacizumab (2)  ·  Carboplatin (2)  ·  Cisplatin (2)  ·  Disulfides (2)  ·  Docetaxel (2)  ·  Immunoglobulin G (2)  ·  Platinum (2)  ·  (225)Ac-DOTA-c(RGDyK) (1)  ·  Cetuximab (1)  ·  Fluorouracil (1)  ·  Magnetic Resonance Spectroscopy (1)  ·  Pilocarpine (1)  ·  Specimen Handling (1)  ·  atezolizumab (1)

Sponsors

National Cancer Institute (NCI) (2)  ·  Radiation Therapy Oncology Group (1)

Countries

United States (3)  ·  Canada (1)  ·  Puerto Rico (1)  ·  South Africa (1)

Top investigators

Aarti Bhatia (1)  ·  Francis G. LeVeque, DDS (1)

Results publications

PMID 12788192, PMID 16724649, PMID 31618129

NIH funding

U10CA180820 (2), U10CA021115 (1)